AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22585212 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric dosing algorithm for miltefosine
Number of subjects: 0
Study 22585212 — intervention group
Group type: EXPERIMENTAL
Intervention: New allometric dosing algorithm for miltefosine
Number of subjects: 0
Study 21092030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P)
Number of subjects: 289
Study 21092030 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (Group NP)
Number of subjects: 289
Study 17885789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh fixation by metal tacks
Number of subjects: 360
Study 17885789 — intervention group
Group type: COMPARATOR
Intervention: Unfixated mesh
Number of subjects: 360
Study 15942317 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS Wound Matrix
Number of subjects: 73
Study 15942317 — intervention group
Group type: COMPARATOR
Intervention: Regranex Gel
Number of subjects: 73
Study 12843202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1 micro g/Kg iv)
Number of subjects: 2
Study 12843202 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 micro g/Kg iv)
Number of subjects: 2
Study 12843202 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus Ghrelin (1 micro g/Kg iv)
Number of subjects: 2
Study 10472341 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog triptorelin (3.75 mg i.m. monthly)
Number of subjects: 21
Study 10472341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of triptorelin and aromatase inhibitor formestane (4‐OHA, 500 mg i.m. fortnightly)
Number of subjects: 21
Study 8933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g creatine monohydrate 4 times per day for 5 days)
Number of subjects: 20
Study 8933496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage of a lactose placebo)
Number of subjects: 20
Study 8933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20
Study 8933496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1655227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2) and Doxorubicin (70 mg/m2) every 3 weeks for four cycles
Number of subjects: 61
Study 1655227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1000 mg/m2 every 21 days for six cycles)
Number of subjects: 61
Study 1655227 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-abdominal radiation therapy
Number of subjects: 61
Study 1655227 — intervention group
Group type: COMPARATOR
Intervention: No treatment (refusal of SLL)
Number of subjects: 61
Study 7058508 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-free diet (abstaining from methylxanthine-containing foods and beverages)
Number of subjects: 158
Study 7058508 — intervention group
Group type: COMPARATOR
Intervention: No dietary recommendations (controls)
Number of subjects: 158
Study 30996057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcranial magnetic stimulation
Number of subjects: 15
Study 30996057 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity sham stimulation
Number of subjects: 15
Study 30309787 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem
Number of subjects: 690
Study 30309787 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 690
Study 30309787 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem (modified intention-to-treat)
Number of subjects: 690
Study 30309787 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (modified intention-to-treat)
Number of subjects: 690
Study 26624976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 800 μg (total dose 800 μg)
Number of subjects: 30
Study 26624976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 400 μg (total dose 400 μg)
Number of subjects: 30
Study 26624976 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate Diskus 400 μg (total dose 400 μg)
Number of subjects: 30
Study 26624976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 800 μg
Number of subjects: 30
Study 26624976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 400 μg
Number of subjects: 30
Study 26624976 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate Diskus 400 μg
Number of subjects: 30
Study 24935879 — intervention group
Group type: EXPERIMENTAL
Intervention: High-valence condition (n = 7)
Number of subjects: 15
Study 24935879 — intervention group
Group type: COMPARATOR
Intervention: Low-valence condition (n = 8)
Number of subjects: 15
Study 22548646 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg, 100 mg, 200 mg, 300 mg daily, or 300 mg twice daily
Number of subjects: 289
Study 22548646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 22548646 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 289
Study 22548646 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 289
Study 22548646 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo/sitagliptin)
Number of subjects: 289
Study 22548646 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 289
Study 20623038 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin
Number of subjects: 506
Study 20623038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 17390738 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Q2W)
Number of subjects: 1101
Study 15818684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 529
Study 15818684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 529
Study 15818684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 12683736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a message from their physician, a self-help manual, written personalized feedback, and up to 3 telephone counseling calls.
Number of subjects: 307
Study 12683736 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 307
Study 10353069 — intervention group
Group type: EXPERIMENTAL
Intervention: Military fighter pilots (group B)
Number of subjects: 100
Study 10353069 — intervention group
Group type: COMPARATOR
Intervention: Military ground personnel (group A)
Number of subjects: 100
Study 7795772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal lactation instruction from a lactation consultant
Number of subjects: 108
Study 7795772 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no lactation consultant)
Number of subjects: 108
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 4-5 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine at 4-5 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Schwarz vaccine at 4-5 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb vaccine for seropositive children
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine for seropositive children
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz vaccine for seropositive children
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 8-10 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz vaccine at 8-10 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: COMPARATOR
Intervention: High-dose Edmonston-Zagreb or AIK-C at 4-5 months
Number of subjects: 5
Study 1819435 — intervention group
Group type: COMPARATOR
Intervention: Standard dose Schwarz at 8-10 months
Number of subjects: 5
Study 7274609 — intervention group
Group type: EXPERIMENTAL
Intervention: CaCl2 (60 mmole orally over 24 h for 3 days)
Number of subjects: 11
Study 7274609 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl2 (60 mmole orally over 24 h for 3 days)
Number of subjects: 11
Study 7274609 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl2 (60 mmole daily)
Number of subjects: 11
Study 7274609 — intervention group
Group type: COMPARATOR
Intervention: Mg(OH)2 (60 mmole daily)
Number of subjects: 11
Study 30520566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin 20 mg daily
Number of subjects: 120
Study 30520566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (1, 5, or 20 mg daily or 20 mg weekly)
Number of subjects: 120
Study 30520566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin 20 mg daily and weekly
Number of subjects: 120
Study 30520566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27785682 — intervention group
Group type: EXPERIMENTAL
Intervention: PM group (learned at 8 pm, tested at 8 am after sleep)
Number of subjects: 56
Study 27785682 — intervention group
Group type: COMPARATOR
Intervention: AM group (learned at 8 am, tested at 8 pm without sleep)
Number of subjects: 56
Study 27785682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AM and PM) after 24 hours
Number of subjects: 56
Study 26222533 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered Tc-sulfur colloid (pH 7.40)
Number of subjects: 60
Study 26222533 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care Tc-sulfur colloid
Number of subjects: 60
Study 24314887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 131
Study 24314887 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 131
Study 24314887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission of depression at week 12
Number of subjects: 131
Study 24314887 — intervention group
Group type: COMPARATOR
Intervention: Nonremission of depression at week 12
Number of subjects: 131
Study 23040570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily for 3 months
Number of subjects: 161
Study 23040570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 23040570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 161
Study 23040570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 161
Study 20020412 — intervention group
Group type: EXPERIMENTAL
Intervention: CondECC
Number of subjects: 75
Study 20020412 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC
Number of subjects: 75
Study 20020412 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 75
Study 17447216 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 65
Study 17447216 — intervention group
Group type: COMPARATOR
Intervention: Levovist
Number of subjects: 65
Study 15053242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH stimulation test
Number of subjects: 22
Study 15053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone test (30 mg/kg orally at 23:00 h)
Number of subjects: 22
Study 15053242 — intervention group
Group type: COMPARATOR
Intervention: Adrenal size comparison
Number of subjects: 22
Study 15842577 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (10 and 20 mg once daily)
Number of subjects: 0
Study 15842577 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 0
Study 15842577 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 0
Study 15842577 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg three times daily)
Number of subjects: 0
Study 10561336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg on alternate days
Number of subjects: 105
Study 10561336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/d
Number of subjects: 105
Study 10561336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 105
Study 10561336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 10999061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HOT)
Number of subjects: 60
Study 10999061 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 60
Study 2060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease patients during stress tests
Number of subjects: 23
Study 2060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome X patients during stress tests
Number of subjects: 23
Study 6362245 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine (N)
Number of subjects: 36
Study 6362245 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbiddinitrate (I)
Number of subjects: 36
Study 6362245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20 mg isosorbiddinitrate and 20 mg nifedipine (I + N)
Number of subjects: 36
Study 6362245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 36
Study 31727687 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers (up to 16 biomarkers) added to routinely measured clinical risk factors
Number of subjects: 7482
Study 31727687 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers (15 biomarkers)
Number of subjects: 7482
Study 31727687 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers (12 biomarkers + 1 additional)
Number of subjects: 7482
Study 31727687 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 0.1 mL/min/1.73 m2 predicted annual fall in eGFR
Number of subjects: 7482
Study 30725411 — intervention group
Group type: COMPARATOR
Intervention: Methionine-restricted total parenteral nutrition (MR TPN) with chemotherapy-containing amino acid solution (AO-90)
Number of subjects: 34
Study 30725411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day methionine-restricted diet combined with cystemustine (60 mg/m2 every 2 weeks)
Number of subjects: 34
Study 30725411 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available methionine-restricted medical food
Number of subjects: 34
Study 30725411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary methionine restriction combined with FOLFOX regimen
Number of subjects: 34
Study 27707530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) 441mg
Number of subjects: 0
Study 27707530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) 882mg
Number of subjects: 0
Study 27707530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26875002 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024% qpm
Number of subjects: 420
Study 26875002 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% BID
Number of subjects: 420
Study 23802645 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE)
Number of subjects: 39
Study 23802645 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse + moist dentin (ERm)
Number of subjects: 39
Study 23802645 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse + dry dentin (ERd)
Number of subjects: 39
Study 23802645 — intervention group
Group type: COMPARATOR
Intervention: Selective enamel etching (Set)
Number of subjects: 39
Study 23802645 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retention
Number of subjects: 39
Study 23802645 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal adaptation
Number of subjects: 39
Study 22889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 39
Study 22889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 39
Study 22889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness
Number of subjects: 39
Study 22889317 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function
Number of subjects: 39
Study 19319508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 56
Study 19319508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17887929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) of parathyroid adenomas
Number of subjects: 30
Study 17887929 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-FNA)
Number of subjects: 30
Study 15679129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 2 mg
Number of subjects: 56
Study 15679129 — intervention group
Group type: COMPARATOR
Intervention: Transnasal placebo
Number of subjects: 56
Study 12622925 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus micronized progesterone (MP) 100 mg/d
Number of subjects: 60
Study 12622925 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Number of subjects: 60
Study 12622925 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus micronized progesterone (MP) 100 mg/d
Number of subjects: 60
Study 12622925 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Number of subjects: 60
Study 12622925 — intervention group
Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 60
Study 9664755 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicin with photoprotective mask
Number of subjects: 54
Study 9664755 — intervention group
Group type: COMPARATOR
Intervention: Placebo with photoprotective mask
Number of subjects: 54
Study 7851681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic euglycaemic hyperinsulinaemia (+72 pmol/l) for 72-96 hours
Number of subjects: 15
Study 7851681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hyperglycaemic hyperinsulinaemia (+78 pmol/l) for 72 hours
Number of subjects: 15
Study 30120832 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block with 30 ml ropivacaine 0.375%
Number of subjects: 89
Study 30120832 — intervention group
Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 89
Study 28477992 — intervention group
Group type: EXPERIMENTAL
Intervention: iNPWT (intervention negative pressure wound therapy)
Number of subjects: 71
Study 28477992 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative (dry gauze) dressing (control)
Number of subjects: 71
Study 26597808 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring for Couples Coping with Cancer '4Cs' Programme
Number of subjects: 0
Study 23143093 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural education program (6 sessions over 6 weeks)
Number of subjects: 137
Study 23143093 — intervention group
Group type: COMPARATOR
Intervention: Usual school curriculum
Number of subjects: 137
Study 21974699 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BHD)
Number of subjects: 44
Study 21974699 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free citrate hemodialysis (AFHD)
Number of subjects: 44
Study 21974699 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-bicarbonate hemodialysis (ReBHD)
Number of subjects: 44
Study 19902462 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16823554 — intervention group
Group type: COMPARATOR
Intervention: SureFil (S)
Number of subjects: 33
Study 16823554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert (A)
Number of subjects: 33
Study 12480080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 0
Study 11080707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric asthma caregiver diary scale
Number of subjects: 125
Study 11080707 — intervention group
Group type: EXPERIMENTAL
Intervention: Day without asthma symptoms (DWAS)
Number of subjects: 125
Study 9709276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening every 18 months
Number of subjects: 25941
Study 9709276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited to screening until the fifth screen)
Number of subjects: 25941
Study 8346826 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA) with 0.5% bupivacaine, initial dose 1 mL, reinjection 1 mL
Number of subjects: 77
Study 8346826 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA) with 0.5% bupivacaine, initial dose 10 mL, reinjection 5 mL
Number of subjects: 77
Study 8346826 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SSA) with 0.5% bupivacaine, initial dose 3 mL
Number of subjects: 77
Study 3721944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 15
Study 3721944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 15
Study 3721944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30285755 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month dietary intervention delivered by promotoras via home visits and telephone calls
Number of subjects: 361
Study 30285755 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month dietary intervention
Number of subjects: 361
Study 30285755 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 361
Study 27283862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 15822
Study 24837481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced contact with interventionist (EC)
Number of subjects: 1838
Study 24837481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced contact with interventionist + skills (EC + skills)
Number of subjects: 1838
Study 24837481 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1838
Study 22330753 — intervention group
Group type: EXPERIMENTAL
Intervention: 6g FPP®/day for 14 weeks
Number of subjects: 0
Study 20701016 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD screening tests (e.g., glomerular filtration rate)
Number of subjects: 0